BTIG Reiterates Buy on Carlsmed, Maintains $23 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.3%

Neg 0% Neu 90.3% Pos 0%

BTIG analyst Ryan Zimmerman reiterates Carlsmed (NASDAQ:CARL) with a Buy and maintains $23 price target.

Comments

No comments yet. Be the first!